Drug Watch

Neurocrine Biosciences launches a phase 2 trial for NBI-1065890.

LB Pharmaceuticals initiates a phase 2 trial for LB-102, a promising treatment for bipolar depression, aiming to address unmet needs in mood disorders.

LPCN 1154 shows promise as a rapid, at-home treatment for postpartum depression, with favorable safety results in ongoing phase 3 trials.

BioXcel Therapeutics submits an sNDA to the FDA for Igalmi to treat agitation in bipolar disorder and schizophrenia at home.

Seltorexant shows promise as a safe adjunctive treatment for patients with major depressive disorder and insomnia symptoms, with fewer weight changes than quetiapine XR.

New data reveals Caplyta significantly improves remission rates in adults with major depressive disorder, offering hope for lasting relief from symptoms.

Centanafadine demonstrates promising effects on ADHD symptoms, enhancing key neurotransmitters without increasing psychomotor activity, according to poster data.

Axsome Therapeutics begins a pivotal trial for AXS-14, aiming to improve fibromyalgia management and address significant patient needs.

New data reveals valbenazine (Ingrezza) shows significantly higher VMAT2 target occupancy than deutetrabenazine (Austedo XR).

Scienture's Rezenopy, the highest-dose naloxone nasal spray approved by the FDA, gains patent protection.

FDA removes suicidal ideation warnings from GLP-1 RA medications, highlighting their potential benefits in weight loss and mental health treatment.

Cassava Sciences shares insights from phase 3 trials of simufilam for Alzheimer disease, revealing potential treatment differences despite unmet primary endpoints.

FDA approves ProlivRx, a groundbreaking at-home therapy for major depressive disorder, offering new hope for patients unresponsive to traditional treatments.

Lipocine's LPCN 1154 shows promise in treating postpartum depression, with a strong safety profile and potential for rapid relief in outpatient settings.

Reviva Pharmaceuticals reveals promising clinical trial data on brilaroxazine, highlighting its potential to treat negative symptoms in schizophrenia.

NTX-253 enters phase 1 trials, exploring a novel approach to schizophrenia treatment with potential for improved safety and efficacy.

Acceptance paves the way for a critical trial of COMP360, a synthetic psilocybin that has the potential to transform PTSD care.

The FDA has granted Breakthrough Therapy designation to Alkermes' alixorexton for narcolepsy type 1, which could offer hope for improved wakefulness and reduced daytime sleepiness.

Cognition Therapeutics shares zervimesine's promising phase 2 results, showing safety and improved symptoms in dementia with Lewy bodies.

Xanomeline/trospium emerges as a groundbreaking schizophrenia treatment, showcasing efficacy and safety while highlighting challenges in clinical adoption.

MapLight Therapeutics advances treatment for Alzheimer disease psychosis with FDA Fast Track designation for ML-007C-MA, targeting hallucinations and delusions.

Biohaven's BHV-7000 fails to reduce depressive symptoms in a phase 2 proof-of-concept study.

What disease states are most prominently featured in recent research? Learn more in this exclusive article.

Check out the pipeline updates from December!

Syremis Therapeutics advances innovative drugs ST-905 and ST-901 for schizophrenia and major depressive disorder, aiming to transform mental health treatment.